APA (7th ed.) Citation

Ren, T., Wang, S., Shen, Z., Xu, C., Zhang, Y., Hui, F., . . . Zhao, Q. (2021). Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Drug Safety, 44(1), 29. https://doi.org/10.1007/s40264-020-00997-2

Chicago Style (17th ed.) Citation

Ren, Tianshu, Shu Wang, Zexu Shen, Chang Xu, Yingshi Zhang, Fuhai Hui, Xingshun Qi, and Qingchun Zhao. "Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis." Drug Safety 44, no. 1 (2021): 29. https://doi.org/10.1007/s40264-020-00997-2.

MLA (9th ed.) Citation

Ren, Tianshu, et al. "Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis." Drug Safety, vol. 44, no. 1, 2021, p. 29, https://doi.org/10.1007/s40264-020-00997-2.